Cancer Cachexia Market Size, Share, By Product (Progestogens, Corticosteroids, Combination Therapies, and Others), By Mechanism of Action (Appetite Stimulators, Weight Loss Stabilizers), By Distributional Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region - Trends, Analysis and Forecast till 2034

Cachexia is a complex metabolic syndrome characterized by severe and progressive weight loss, mainly due to the depletion of skeletal muscle mass and adipose tissue. This condition occurs more frequently in patients with advanced cancer, especially of the pancreas, lung, and gastrointestinal tract origins. Cachexia is different from simple starvation or anorexia because it involves a concrete interaction among the tumor, the host's immune system, and diverse metabolic pathways. The hallmark of cancer cachexia is a formidable metabolic alteration. Resting energy expenditure increases, being part of the negative energy balance characterizing the patient with cancer cachexia. In cancer cachexia, normal responses of the whole organism to reduced food intake, consistently characterized by low CO2 production, are impaired. This is to say that the body still burns out calories at a high rate with inadequate nutrition intake.

One of the hallmark features of cancer cachexia is the severe loss of skeletal muscle mass. This is mediated by several mechanisms, which involve increased protein degradation via the ubiquitin-proteasome pathway and autophagy and entail a decrease in protein synthesis. The muscle loss contributes not only to the physical strength and functionality of the patient but also to his quality of life and his capability to withstand cancer treatments. Anorexia, another essential pillar of cancer cachexia, quite literally corresponds to the state of losing appetite. This can be due to changes in taste and smell, post-cancer treatment nausea, and a direct mechanism by pro-inflammatory cytokines acting on the hypothalamus, leading to decreased appetite. This poor dietary consumption worsens the state of negative energy balance, and thus, weight loss is facilitated.

Diagnosis involves weight loss, body mass index, and decreased muscle strength. Cachexia gradually becomes resistant to reversal with its progression, so early recognition is important. Treatment modalities are complex and may comprise nutritional support, exercise interventions, and pharmacological therapies targeting inflammation and hypo-phagia. Although cancer cachexia is one of the poorest conditions that a cancer patient can develop, it is a problematic clinical syndrome subject to an effective method of treatment. Presently, research has focused on developing targeted therapy to address the underlying metabolic and inflammatory processes driving this syndrome. Understanding and successful treatment of cancer-related cachexia would be very vital to the improvement of the quality of life, treatment outcome, and overall survival of cancer patients.

Cancer Cachexia Market Size

• The Cancer Cachexia Market was valued at USD 2.45 Billion in 2024.
• It is projected to grow to USD 3.6 Billion by 2034.
• The market is expected to grow at a CAGR of 4.3% during this period.

                             To Know More, Request Free Sample Report

Key Drivers of Target Market:

Growing prevalence of cancer:

• Increasing cancer incidence around the world, especially in the geriatric population, is the prime driver for the market of cancer cachexia. With more people being diagnosed with this dreaded disease, the demand for effective treatment for cachexia—which is a common complication—has also been on the rise.

Limited treatment options:

• With limited treatment alternatives, presently administered treatments for cancer cachexia are poorly effective, often related incidentally to prohibitory side effects. In the face of this substantial unmet medical need, research and development towards discovering and developing more effective therapies are gearing growth in the market.

Improved understanding of cachexia:

• Indeed, the better understanding of cachexia: Advances in research have provided a view of the mechanisms behind cancer cachexia, which is helping develop adequate treatment approaches dealing with the specific causative factor, which is involved in loss of muscle mass and body weight. Subsequently, this provides a roadmap for entering new markets.

Restrains:

High treatment costs:

• Developing and manufacturing a novel therapy for cancer cachexia can be very costly, and that will make the treatment expensive. High costs in developing treatment may quickly render access to most patients, particularly those in low- and middle-income countries, hence not promoting market growth.

Opportunities:

New therapeutic interventions:

• The discovery of various new therapeutic interventions to aid in the management of cancer cachexia is still under investigation; these could include target therapy, biologics, and their combinations. The market size is very much dependent on their success rate.

The market is segmented based on Product, Mechanism of Action, Distributional Channel, and Region.

Product Insights:

• Progestogens: Progestogens, like megestrol acetate, are also commonly used in the management of cancer cachexia, as they increase appetite and cause weight gain. It is one of the most widely prescribed treatments for this condition.
• Corticosteroids: Corticosteroids, such as dexamethasone, are used for their anti-inflammatory activity but also have an orexigenic effect, leading to an increased caloric intake. The long-term use of dexamethasone is limited by side effects such as muscle wasting and immunosuppression.
• Combination Therapies: Such therapies are the combinations of multiple agents encompassing progestogens with corticosteroids and other drugs to take care of the diversity of factors associated with cachexia. Here, the best value is given to obtaining the maximum effects with the least possible side effects. Simply put, this means minimizing the side effects of the drugs and thus offering a complete approach to the treatment.
• Others: This includes a range of upcoming treatments, including ghrelin agonists, anti-inflammatory agents, and anabolic steroids. These treatments are still under experimental investigation, and their role will be felt in future treatment modules.

Mechanism of Action Insights:

• Appetite Stimulators: These agents act by increasing appetite and caloric consumption. It directly treats one of the main symptoms of cancer cachexia. Drugs under this category include megestrol acetate and ghrelin mimetics, which help raise food intake and stabilize weight.
• Weight Loss Stabilizers: These are agents that prevent or slow down muscle loss and body weight. The mechanism of action is believed to be through the action of the metabolic pathways involved in muscle degradation, providing a protective effect against severe wasting observed in cachexia patients.

Distributional Channel Insights:

• Hospital Pharmacy: Hospital pharmacies are the most effective access site for delivering drugs to treat cancer cachexia, particularly to oncology inpatients when quick access to the necessary medications is needed under medical care, as is often the case for patients with advanced cancer.
• Retail Pharmacy: A retail pharmacy is an essential delivery site for treating outpatients and is particularly useful in the ambulatory phase of managing cancer cachexia. Patients can quickly go there to refill their regular medication and seek consultancy.
• Online Pharmacy: These have been on the rise, and online medication delivery for cancer cachexia has become very popular, with home delivery services. This is especially useful for immobile cancer patients and those living in distant places.

Regional Insights

• North America: Owing to its rising incidence of cancer, developed healthcare infrastructure, and high R&D moves, North America emerges as a leading cancer cachexia market. It has dominant key pharmaceutical companies in this region supplying cancer cachexia drugs with vigorous health policies.
• Asia Pacific: The Asia Pacific market is expected to be the fastest-growing, driven by the rising incidence of cancer, improved healthcare infrastructure, and better access to advanced treatment. Major markets in the region include China and India.
• Europe: Europe commands a good share of the market owing to well-established healthcare systems in this region and the rising awareness regarding cancer cachexia. Also, investment in research and development for new therapies is rising.
• Latin America: The market in Latin America is growing steadily, supported by improving healthcare access and raising awareness about cancer cachexia. However, the market is still impacted by economic constraints and the inadequacy of advanced therapies.
• Middle East and Africa: This region has a small market share due to poor healthcare infrastructure and limited treatment access. The increased investment in the healthcare sector and awareness of the disorder might provide future growth opportunities.

Cancer Cachexia Market Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the target market report based on Product, Mechanism of Action, Distributional Channel, and Region.

Segmentation:

By Product:

• Progestogens

• Corticosteroids
• Combination Therapies
• Others

By Mechanism of Action:

• Appetite Stimulators
• Weight Loss Stabilizers

By Distributional Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Cancer Cachexia Market include AbbVie Inc., Actimed Therapeutics, Aeterna Zentaris Inc., ANI Pharmaceuticals Inc., Aphios Corporation, Aveo Pharmaceuticals Inc., Bristol-Myers Squibb Company, Helsinn Group, Hikma Pharmaceuticals PLC, Merck & Co. Inc., Mylan N.V., Pfizer Inc., TCI Peptide Therapeutics, Teva Pharmaceutical Industries Ltd.

                     To Access More Companies, Download Free Sample PDF

• In February 2024, Meta Fines, a medicine repositioning business, announced that it had reached a licensing agreement with BMI Korea for its cancer cachexia treatment. According to the agreement, BMI Korea will co-own the global technology transfer rights of ASCA101_CC with Meta Fines. It will have the option to license the product in certain regions, including Korea and Southeast Asia. BMI Korea will pay Meta Fines 2 billion won ($1.51 million) up front, followed by 46 billion won in tiered milestone payments.  ASCA101_CC is a pipeline that targets cancer cachexia.
• In February 2024, Pfizer is banking on cancer treatments to help it regain its footing after a challenging year marked by a fast decrease in its Covid business. The pharmaceutical company has been attempting to bolster investor enthusiasm after its stock plunged more than 40% in 2023. Pfizer claims its combined medication pipeline with cancer company Seagen could result in at least eight blockbuster treatments by 2030. With Seagen under its belt, Pfizer believes its medical pipeline will generate at least eight blockbuster drugs by 2030, up from five today. However, the business did not specify which treatments it believes have such potential.

• AbbVie Inc.
• Actimed Therapeutics
• Aeterna Zentaris Inc.
• ANI Pharmaceuticals Inc.
• Aphios Corporation
• Aveo Pharmaceuticals Inc.
• Bristol-Myers Squibb Company
• Helsinn Group
• Hikma Pharmaceuticals PLC
• Merck & Co. Inc.
• Mylan N.V.
• Pfizer Inc.
• TCI Peptide Therapeutics
• Teva Pharmaceutical Industries Ltd.

Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Product
  • Market Snippet, By Mechanism of Action
  • Market Snippet, By Distributional Channel
  • Market Snippet, By Region
• Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Market Trends
• Product Launch
• Merger and Acquisitions
• Impact Analysis
• PEST Analysis
• Porter’s Analysis

Market Segmentation, By Product, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Progestogens
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Corticosteroids
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Combination Therapies
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Mechanism of Action, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Appetite Stimulators
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Weight Loss Stabilizers
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Distributional Channel, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Hospital Pharmacy
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Retail Pharmacy
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Online Pharmacy
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Region, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (USD Bn), By Product, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Mechanism of Action, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Distributional Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • U.S
    • Canada
• Asia Pacific
  • Market Size and Forecast (USD Bn), By Product, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Mechanism of Action, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Distributional Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Europe
  • Market Size and Forecast (USD Bn), By Product, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Mechanism of Action, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Distributional Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • UK
    • Germany
    • France
    • Russia
    • Italy
    • Rest of Europe
• Latin America
  • Market Size and Forecast (USD Bn), By Product, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Mechanism of Action, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Distributional Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • Brazil
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Market Size and Forecast (USD Bn), By Product, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Mechanism of Action, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Distributional Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East and Africa

Competitive Landscape

• Heat Map Analysis
• Company Profiles

• AbbVie Inc.
• Actimed Therapeutics
• Aeterna Zentaris Inc.
• ANI Pharmaceuticals Inc.
• Aphios Corporation
• Aveo Pharmaceuticals Inc.
• Bristol-Myers Squibb Company
• Helsinn Group
• Hikma Pharmaceuticals PLC
• Merck & Co. Inc.
• Mylan N.V.
• Pfizer Inc.
• TCI Peptide Therapeutics
• Teva Pharmaceutical Industries Ltd.

The Last Word

• Future Impact
• About Us
• Contact